Ethics Council discusses expensive medicines
For some rare diseases that used to be hardly treatable, there now exist highly effective but sometimes extremely expensive drugs. Prices such as two million euros per single dose, or 275,000 euros for one year of treatment, are fraught with a number of ethical issues, especially given that more high-priced drugs are expected to be launched in the years to come. The interests of all insured persons to receive the best possible treatment, but also the demands of pharmaceutical companies to refinance research investments, must be weighed against the requirement to prevent boundless increases in health care costs and, in particular, health insurance contributions.
Considering the need for sustainable and responsible procedures despite limited resources, the German Ethics Council, on the occasion of its annual meeting in 2022, would like to stimulate ethical debate on how to deal with issues surrounding new expensive medicines in solidary and fair ways.
What leads to high prices and how can they be justified in a solidarity-based health care system? How can the availability and fair allocation of cost-intensive medicines be improved? How can fair allocation also be achieved at an international level, given global disparities in access to resources as well as diverse health care systems?
The annual meeting will be held as an in-person event for the first time since 2019. The event will also be broadcast via livestream.
Further information, including on the programme and registration, is available on the German Ethics Council’s website at https://www.ethikrat.org/en/annual-meetings/steep-prices-speedy-recovery.